GW Pharmaceuticals is a world leader in discovering, developing and commercializing novel cannabinoid prescription medicines for people living with severe diseases. For more than 17 years, GW has been researching the company’s proprietary cannabinoid product platform. GW commercializes Sativex®, approved for the treatment of spasticity due to Multiple Sclerosis in 27 countries, and is dedicated to advancing orphan drug programs in rare pediatric epilepsies with a focus on Epidiolex® (cannabidiol), currently in Phase 3 clinical development for the treatment of Dravet and Lennox- Gastaut syndromes and is expected to enter Phase 3 clinical trials for the treatment of Tuberous Sclerosis Complex by the end of 2015. GW has a deep pipeline of additional cannabinoid product candidates in clinical development as a potential treatment of pain associated with advanced cancer, neonatal hypoxic ischemic encephalopathy (NHIE), glioma, schizophrenia, ulcerative colitis and type 2 diabetes. For further information, please visit www.gwpharm.com.